2016 年第 6 期 第 14 卷

HPV16-E6-DNA病毒载量对宫颈癌患者生存状况的预测效果

作者：

单位：

关键词：宫颈癌人乳头瘤病毒预后

• 摘要：
• 【摘要】目的 探讨宫颈癌组织中人乳头瘤病毒16型致癌基因E6（HPV16-E6-DNA）的病毒载量对宫颈癌患者生存状况的预测效果。方法选取126例宫颈癌患者为研究对象，提取宫颈组织DNA，利用荧光定量PCR技术检测宫颈癌组织中HPV16-E6-DNA病毒载量，根据检测的HPV16-E6-DNA载量将患者分为HPV16-E6-DNA低载量组（＜106copy/ng）与HPV16-E6-DNA高载量组（≥106copy/ng）。采用Kaplan-Meier法计算两组患者的生存率，采用Cox模型对影响患者5年生存率的因素进行分析。结果不同HPV16-E6-DNA载量患者间年龄、FIGO分期及淋巴结转移情况差异有统计学意义（P＜0.05）。Kaplan-Meier生存率分析显示：HPV16-E6-DNA低载量组患者1年、3年及5年生存率分别为95.67%、89.32%、74.29%，HPV16-E6-DNA高载量组患者1年、3年及5年生存率分别为89.09%、62.60%、51.37%，差异有统计学意义（P＜0.05）。Cox多因素回归分析结果显示：HPV16-E6-DNA病毒载量及淋巴结转移是影响宫颈癌患者预后的主要因素。结论HPV16-E6-DNA病毒载量与宫颈癌患者的远期预后密切相关，可作为术后宫颈癌患者预后的预测因子。
• Objective To investigate the predictive effect of oncogenes E6 of human papillomavirus type 16 (HPV16-E6-DNA)on survival situation in patients with cervical cancer. Methods 126 patients with cervical cancer were selected for the study.DNA were extracted fromcervical tissue.Viral load of HPV16-E6-DNA weredetected byfluorescence quantitative PCR technology.According to the results of HPV16-E6-DNA load, patients were divided into lowHPV16 -E6-DNA load group (<106copy / ng) andhigh HPV16-E6-DNA load group (≥106copy / ng). Survival rate wascalculated by Kaplan-Meier in two groups of patients, and the factors affecting the 5-year survivalwere analyzed by Cox model. ResultsAge, FIGO stage and lymph node metastasisbetween two groupwas statistically significant difference (P <0.05). Kaplan-Meier survival analysis showed:1-year, 3-year and 5-year survival rates of low HPV16-E6-DNA load groupwere 95.67%, 89.32% and 74.29%; 1-year, 3-year and 5-year survival rates of high HPV16-E6-DNA load group were 89.09%, 62.60%, 51.37%, and the difference was statistically significant (P <0.05). Cox multivariate regression analysis showed: HPV16-E6-DNA viral load and lymph node metastasis were the main prognostic factor in patients with cervical cancer. Conclusion HPV16-E6-DNA viral load was closely associated with the long-term prognosis of patients with cervical cancer, which can be used as postoperative prognostic factorin patients with cervical cancer.